To read more on these records and others in the pharmaceutical arena, please visit Clarivate Analytics Cortellis, where you may access full pdf documents of the same, along with expert analysis and indexing of their content to accompany detailing of such aspects as expirations, infringements, licensing and exclusivity.

The Patent Gazette provides snapshot analysis and indexing of pharmaceutically relevant patenting within days of its publication by patent offices. Primarily focusing on material from the main three patents offices (i.e., the EPO, USPTO, and WIPO), it provides brief descriptions of a patent’s content and seeks to link it to both prior patenting of relevance and to any commercial activity pertinent to the technology being described.

Subscription and access to Cortellis may be tailored and restricted to particular subject areas of interest, such as only its patenting content. For more details please do contact us.

Patent schematic of an anterior lumbar interbody fusion device

WO2020113276-A1: “An implantable medical device.”

Assignee: 3DMorphic Pty Ltd

Inventors: Mobbs, Ralph Jasper; Parr, William Chase Harington

IPC Codes: A61F 2/38; A61F 2/44; A61F 2/32

Publication Date: 11-Jun-2020

Earliest Priority Details: AU2018904650, 06-Dec-2018

Customized implantable medical devices that seek to provide a personalized device that can be manufactured and provided at a reduced cost, due to the use of generic component-engaging parts, whilst maintaining the benefits of personalized devices in terms of device-anatomy fit. The implantable medical devices also reduce the volume of 3D printed material that is needed to produce a personalized medical device, which reduces the cost per unit of personalized devices as 3D printing manufacturing costs are based on the volume of material to be manufactured.

For prior patenting in which one of the team, Parr, described a method and system for producing a digital model of a customized device, see WO2017127887. The other inventor, Dr Ralph Mobbs, is a Spinal Neurosurgeon at the Prince of Wales Private and Public Hospitals in Sydney, Australia.

As evidenced from its patenting, the Australian assignee 3DMorphic is aiming to optimize the personalization of orthopedic devices through a technology platform that rapidly customizes generic implant designs while maintaining device integrity. In doing so, cost and time in the operating room is dramatically improved while reducing risk to patients. This the company says enables health care providers to offer patients personalized devices where it would not otherwise be possible.


WO2020117857-A1: “Extended wear ambulatory electrocardiography and physiological sensor monitor.”

Assignee: Bardy Diagnostics Inc

Inventors: Bardy, Gust H.; Bishay, Jon M.; Felix, Jason; Green, Joshua D.

IPC Codes: A61B 5/0408; A61B 5/00

Publication Date: 11-Jun-2020

Earliest Priority Details: US2018208468, 03-Dec-2018

Wearable electrocardiography and physiological sensor monitor that includes two components, a flexible extended wear electrode patch and a removable reusable monitor recorder. The wearable monitor sits centrally (in the midline) on the patient’s chest along the sternum oriented top-to-bottom. The placement of the wearable monitor in a location at the sternal midline (or immediately to either side of the sternum), with its narrow “hourglass”-like shape, benefits long-term extended wear by removing the requirement that ECG electrodes be continually placed in the same spots on the skin throughout the monitoring period. Instead, the patient is free to place an electrode patch anywhere within the general region of the sternum, the area most likely to record high quality atrial signals or P-waves. In addition, ensuring that the level of quality of ECG recording and patient service remains constant over an extended period of time is provided through self-authentication of electrode patches (and other accessories). Published alongside WO2020117859-A1, describing an extended wear electrocardiography patch.

The patent applications’ disclosures reference several US family members of WO2015048182, pertaining to aspects of electrocardiography and physiological sensors, as being incorporated by reference in their entirety. Within their background sections, the applications also explicitly make mention of how the devices being described bestow significant advantages over San Francisco, California-based iRhythm Tech Inc’s Zio® XT Patch and Zio® Event Card wearable stick-on monitoring devices that are typically worn on the upper left pectoral region to respectively provide continuous and looping ECG recording.

In January 2020, Seattle, Washington-based Bardy Diagnostics Inc (BardyDx), of which the inventor Gust Bardy is founder and CEO, announced the commercial launch of the 14-day version of the Carnation Ambulatory Monitor (CAM™), that it describes as being the industry’s only P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device - following the device’s clearance by the US FDA in September 2019. The significance of the CAM™ Patch’s P-wave centric clinical value was highlighted in the American Heart Journal in May 2018 that published the results of a head-to-head comparison with the iRhythm Zio® XT patch, concluding that the BardyDx CAM™ Patch identified 40% more arrhythmias and resulted in better, more informed clinical decision-making in 41% of patients over the iRhythm Zio® XT patch.


US20200185071-A1: “Facilitating sexually transmitted infection services.”

Assignee: Binx Health Ltd

Inventors: Luber, Jeffrey

IPC Codes: C12N 15/113; G06F 21/32; G16H 50/80; G16H 10/60; G16H 10/20; G16H 15/00

Publication Date: 11-Jun-2020

Earliest Priority Details: US2018777561, 10-Dec-2018

Systems and methods to facilitate services related to sexually transmitted infection (STI) testing and therapy. The invention relates to secure systems, methods, and devices for receiving, generating and managing user health data, creating user-specific profiles, and controls to facilitate requisition and delivery of services and products related to diagnostic testing and therapy. User-specific devices may be used to facilitate said STI services, provide information to a user and to collect information about a user.

Jeffrey Luber is CEO of Binx Health, that has operations both in the UK and in Boston, Massachusetts. In April 2020, the company announced it had received a second 510(k) clearance from the US FDA for its molecular point-of-care (POC) testing platform, the binx io®, to market it for the detection of chlamydia and gonorrhea - the two most tested-for STIs globally - in male urine specimens. The company previously announced, in August 2019, the US FDA’s 510(k) clearance of the binx io® for use with clinician and self-collected vaginal swab specimens.

The binx io® platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing a sample-to-answer result in about 30 minutes for the detection of chlamydia and gonorrhea.

For prior patenting describing a method for detecting Neisseria gonorrhoeae in a sample, see WO2016042333 that was published in the assignee’s former name of Atlas Genetics.


WO2020117918-A1: “Determining the rising levels of circulating ketone bodies in a physiological fluid.”

Assignee: Biolinq Inc

Inventors: Peyser, Thomas Arnold; Sjolund, John; Tangney, Jared; Windmiller, Joshua

IPC Codes: A61B 5/145; G01N 33/64

Publication Date: 11-Jun-2020

Earliest Priority Details: US2018777053, 07-Dec-2018

Devices and methods for generating actionable alerts to a user via measurement of circulating ketone body levels in physiological fluids of said user by means of a skin-worn analyte-selective sensor. The sensor may also be configured to simultaneously measure glucose circulating in a physiological fluid of the wearer. The invention is particularly aimed towards providing a method of generating an alarm to a person with diabetes, informing the person of an increased risk of increased and/or elevated ketone levels and alerting them to the need for treatment to prevent progression to diabetic ketoacidosis.

In March 2019, San Diego, California-based Biolinq announced the raising of an additional $4.75 million to a series A round of funding that would help support additional clinical trials and development of its coin-sized sensor patch for monitoring blood glucose levels and other biomarkers. Biolinq hopes its biosensor patch will provide a painless, needle-free method for continuously measuring blood glucose levels. By using a silicon-based microarray to measure biomarkers in the interstitial fluid, the battery-powered patch is designed to wirelessly feed the information to a smartphone app.

For prior patenting in which the inventors and Biolinq co-founders, Tangney and Windmiller described implantable, analyte-selective electrochemical sensors, see WO2018071265.


US20200178820-A1: “Method and arrangement for continuously estimating blood pressure.”

Assignee: Bittium Biosignals OY

Inventors: Ruha Antti

IPC Codes: A61B 5/024; A61B 5/021; A61B 5/0285; A61B 5/0245

Publication Date: 11-Jun-2020

Earliest Priority Details: US 2018216251, 11-Dec-2018

The application describes an estimation method for combining an electrocardiographic signal and a photoplethysmographic signal from a patient to give an estimate of blood pressure.

In March 2018, Bittium Medanalytics and RemoteA entered an agreement whereby Bittium purchased RemoteA’s medical remote diagnostic service platform and the product rights of the related medical measurement devices. This appears to have included a third-party blood pressure measurement device.

The present application appears to be the first application from Bittium on blood pressure measurement.


US20200179696-A1: “Suppressing seizures with low frequency stimulation of the corpus callosum.”

Assignee: Case Western Reserve University

Inventors: Durand, Dominique M; Couturier, Nicholas H

IPC Codes: A61N 1/36

Publication Date: 11-Jun-2020

Earliest Priority Details: US 2018775980, 06-Dec-2018

The application describes a method for applying low frequency stimulation (less than 50 Hz) to the corpus callosum of a patient to reduce hyper-excitability and hence seizures.

This appears to be the first application from the inventors on a treatment for hyper-excitability but see, “Corpus callosum low-frequency stimulation suppresses seizures in an acute rat model of focal cortical seizures” in Epilepsia 2018:59:2219-2230.

The present application continues the interests of one of the team, see eg US20180264255 on neural electrodes and their implantation.


WO2020115485-A1: “Antimicrobial material.”

Assignee: Copper Clothing Limited

Inventors: Donnelly, Rory

IPC Codes: A01N 59/16; A61L 15/00

Publication Date: 11-Jun-2020

Earliest Priority Details: GB 201819857, 05-Dec-2018

The application describes an antimicrobial material comprising a substrate coated with a copper zinc alloy. The application appears to be directed towards wound healing and the treatment of diabetic ulcers.

The company supplies a range of copper treated clothing and fabric products including a copper infused KN99 face mask and copper infused compression gloves. The company has recently disclosed that recent tests on copper fabrics have shown they destroy coronavirus.

This appears to be the first application from the company but continues the interests of the inventor in antimicrobial fabrics, see GB2527846.


US20200179040-A1: “Systems and methods for therapeutic nasal neuromodulation.”

Assignee: Neurent Medical Limited

Inventors: Townley David; Shields Brian

IPC Codes: A61B 18/14

Publication Date: 11-Jun-2020

Earliest Priority Details: US 2018778233, 11-Dec-2018

Nine co-published applications, US20200179040, ‘041, ‘042, ‘043, ‘679, ‘680, ‘681, ‘682 and ‘683, describe a device for the treatment of rhinitis. The device, which is disclosed as minimally invasive, is inserted into the nostril where it deploys a series of electrodes. The electrodes deliver energy to the surface of the inside of the nostril, causing the formation of lesions which interrupt neural signals that cause the production of mucus.

Neurent Medical is a spin-out from the National University of Ireland and in May 2018 raised Eur 9.3 million in series A funding.

The applications appear to be the first from the company but continues the interests of the inventors see eg US20200171302 on methods for evaluation nasal neuromodulation.


WO2020117524-A1: “Apparatus for delivery of radioembolization microspheres.”

Assignee: Sirtex Medical Inc

Inventors: Drake, Jesse; Mccarthy, Justin; Parrott, David; Rose, Joshua; Thrailkill, Patrick T; Gallagher, Charlotte A; Cutuli, Kate; Thompson, Diana Sulas

IPC Codes: A61J 1/05; A61J 1/14

Publication Date: 11-Jun-2020

Earliest Priority Details: US2018774620, 03-Dec-2018

The application describes an easier to use delivery system for radioembolization microspheres. The application discloses that the current systems for SIRT (selective internal radiation therapy) can be cumbersome to use and can also deliver microspheres in non-uniform pulses.

Sirtex makes Y-90 containing resin microspheres (SIR-Spheres) which have been approved in several countries for the treatment of inoperable liver tumors.

In February 2020 Sirtex announced it had acquired 8.8% of the outstanding stock in OncoSec Medical Inc and will support premarketing activities for OncoSec’s TAVO and Visceral Lesion Applicator products.

The present application continues the company’s interests in delivery systems for therapeutics see WO201649685 on a device for administering a therapeutic substance.


WO2020118091-A1: “Ondansetron in-adhesive transdermal patch.”

Assignee: Starton Therapeutics Inc

Inventors: Borovinskaya, Marina; Lather, Tamanna; Modi, Nisarg; Plakogiannis, Fotios

IPC Codes: A61K 9/70; A61K 31/4178; A61P 1/08; A61K 47/14; A61K 47/10; A61K 47/20; A61K 47/12

Publication Date: 11-Jun-2020

Earliest Priority Details: US2018775543, 05-Dec-2018

Ondansetron in-adhesive transdermal patches, and transdermal formulations for self-adhesive polyacrylic pressure sensitive adhesive (PSA) patches that include an amphiphilic polymer. Embodiments of the invention allow the formulation to be adapted to provide an increased flux and an improved flux profile with a more rapid onset and longer duration of steady state. This allows a more tailored treatment of patient groups and symptoms, particularly for chemotherapy induced nausea and vomiting (CINV), which requires a high initial flux in the acute phase that is sustained over multiple days or weeks.

In December 2019, New York-based ChemioCare USA Inc announced it was rebranding itself Starton Therapeutics as it sought to evolve from being a cancer supportive care focused-company into a wider range of therapeutic areas, including hematology and cancer therapeutics beyond chemotherapy. To this end, in April 2020, Starton Therapeutics announced that it had filed PCT and US non-provisional patent applications, entitled, “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” (PCT application number PCT/US20/29159 and US application number 16/854,810).

The core of the company’s business is its transdermal technology, which uses adhesive patches to deliver generic medicines via the skin. Unlike patches that must be replaced every six to eight hours, Starton Therapeutics’ products release drugs in a controlled and sustained way over the course of five to seven days. It currently has three patches in development for cancer and palliative care and expects to enter pivotal phase 3 pivotal studies during 2020.

In January 2019, the company announced that it was adapting and tailoring its five-day adhesive transdermal patch, CMIO-ONDAN, which delivers the 5-HT3 receptor antagonist ondansetron to treat CINV in adults towards pediatric CINV, noting that pediatric CINV does not have any approved treatments for the delayed phase of CINV in highly emetogenic chemotherapy.

For prior patenting in which Plakogiannis (one of Starton’s co-founders) described transdermal patches for the delivery of liquid or gel formulations of either fluoxetine or olanzapine, alone or in combination with each other, see WO2014172344.


WO2020118256-A1: “Systems and methods for prevention of pressure ulcers.”

Assignee: University of Massachusetts; Worcester Polytechnic Institute

Inventors: Abujrida, Hamza; Dunn, Raymond; McNeill, John; Mendelson, Yitzhak

IPC Codes: A61B 5/00; A61B 5/1495; A61B 5/021; A61B 5/024; A61B 5/145; A61B 5/107

Publication Date: 11-Jun-2020

Earliest Priority Details: US2018212576, 06-Dec-2018

Devices and methods for detecting the formation of pressure ulcers. A pressure sensor device generates patient pressure data that is processed by a data processor which utilizes a diagnostic function to determine a diagnostic value that indicates whether corrective action is needed to prevent pressure ulcer formation. One or more sensor devices can be attached to a patient to measure to transmit data for further processing.

The invention is a continuation-in-part of Dunn, McNeil and Mendelson’s similarly themed WO2017214188 application, and the technology being described in their patenting can be seen to feature as UMMS16-69 on the BRIDGE website of the University of Massachusetts’ Offices of Technology Management and Business Development and Innovation.

The team’s wireless sensor patches can be placed on known at-risk sites on the patient’s skin, directly measuring local contact pressure and temperature, and communicate with a base station (in a hospital setting) or smartphone (for home care). Alerting a patient or caregiver to a potentially harmful level of pressure allows early intervention (only when necessary) to prevent pressure ulcer formation, easing workload on caregivers and enabling more independence for mobile at-risk patients.


WO2020118190-A1: “Endobronchial catheter system and method for rapid diagnosis of lung disease.”

Assignee: Veran Medical Technologies Inc

Inventors: Holsing, Troy; Hunter, Mark; Lee, Christopher

IPC Codes: A61B 1/267; A61B 10/02; A61B 10/04; A61B 8/08; A61B 8/12; G06T 7/00; A61B 34/20; A61B 8/00; A61M 25/01

Publication Date: 11-Jun-2020 (shares priority details with co-published WO2020118193-A1, US20200179062-A1, and US20200178931-A1)

Earliest Priority Details: US2018776667, 07-Dec-2018

Endobronchial catheter systems integrating both electromagnetic navigation and ultrasonic imaging and backscatter evaluation for use within the lung to provide a diagnosis of cancer. Published alongside WO2020118193, describing a similar such percutaneous catheter system and method rapid diagnosis of lung disease.

In October 2019, St Louis, Missouri-headquartered Veran Medical announced the enrolling of its first patient in a multi-center study evaluating a new method of identifying pulmonary nodules during lung cancer surgeries. The study would use the company’s SPiN Thoracic Navigation System™ that converts CT scans into precise 3D maps used to navigate the airways in the lungs. Veran’s Always-On Tip Tracked® sampling instruments contain small electromagnetic sensors in the tips to help guide physicians to the nodules. Veran’s proprietary SPiN Perc™ technology, which will be used in this study, provides physicians the ability to use a navigated percutaneous approach to reach and mark small nodules outside of airways.

For prior patenting in which Holsing and Hunter described catheter systems incorporating imaging assemblies for detecting, sampling, staging and/or treating target tissues in the lungs, see WO2016183226.

Prior to joining Veran Medical, Holsing and Hunger were key figures at Surgical Navigation Technologies Inc, helping in the development of its StealthStation® Image Guided Surgery System for Neurosurgery that led to the company’s 1995 acquisition by Sofamor Danek (that was then itself purchased by Medtronic in 1998 and rebranded Medtronic Navigation).

No Comments